To Determine the Safety and Immunogenicity of an Oral(Whole Cell) Euvichol Cholera Vaccine in Healthy Adult Men

Phase 1

Completed

• Conditions: Prevention Harmful Effects

• Registration Number: NCT01707537
• Lead Sponsor: EuBiologics Co.,Ltd

Brief Summary

To Determine the Safety and Immunogenicity of an Oral(Whole Cell) Euvichol Cholera Vaccine in Healthy Adult Men

Detailed Description

This clinical trial is open, non-comparative phase 1 clinical studies in healthy men and has been designed to determine the safety and immunogenicity of Euvichol(Oral cholera vaccine)

Study Timeline

• Study Start: 2012-09
• Study First Submitted: 2012-10-09
• Study First Submitted QC: 2012-10-14
• Study First Posted: 2012-10-16
• Status Verified: 2013-02
• Primary Completion: 2013-02
• Study Completion: 2013-02
• Last Update Submitted: 2013-02-18
• Last Update Posted: 2013-02-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 20

Inclusion Criteria

• Adult men over 20years of age
• More than 45kg body weight and ideal body weight within ±20% of the weight
• Screening was conducted within 14 days of investigational drug administration (Vital Sign & Physical Examination, hematology and blood coagulation tests, blood chemistry tests, urinalysis, 12-lead ECG, etc.), the results at the discretion of the investigator deemed suitable for participation in clinical trials
• Written consent person who determines to participate in a clinical trial

Exclusion Criteria

• A person who showed hypersensitivity when other preventive vaccination in the past
• A person who have received cholera vaccine in the past
• A person who had a febrile illness or infection disease, or have received antibiotics within 2weeks before the start of the experiment
• A person who had gastrointestinal symptoms such as diarrhea, abdominal pain, or have been received prescription drug within one week before the start of the experiment
• A person who was lasted for more than two weeks of symptoms such as diarrhea, abdominal pain within 6months before the start of the experiment
• A person who donate whole blood or component of blood within one months before the start of the experiment if the donors
• A person who received other preventive vaccine within 2months before the start of the experiment
• A person who received blood products of immune globulin preparations within 3months before the start of the experiment
• A person who has immune function disorders or are receiving immunosuppressive treatment
• A person who has chronic illness in progress
• Ongoing drug and alcohol abuse(Not more than 28 units/week for drinking)
• A person who participate in clinical trials treated with the investigational drug within 2months before the start of the experiment
• A person who is difficult to participate in this clinical trials as the discretion of the investigator

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Safety(proportion of subjects with adverse events)	From the date of the first orally administered for 4 weeks after the second dose	The proportion of all adverse event and serious adverse event which were occured during the entire study period is analyzed and casuality between severity and investigational product is presented.; Check the vital signs, physical examination and clinical laboratory tests

Secondary Outcome Measures

Name	Time	Method
Immunogenicity(vibriocidal antibody assay)	Baseline(before the administration), 14 days after first dose, 14 days after second dose	Proportion of subjects exhibiting 4-fold or greater rises in titers of serum vibriocidal antibodies, relative to baseline

Trial Locations

Locations (1)

Chungnam National University Hospital; 🇰🇷 Daejeon, Chungnam, Korea, Republic of